Search by Drug Name or NDC

    NDC 00024-5747-02 ADLYXIN 100 ug/mL Details

    ADLYXIN 100 ug/mL

    ADLYXIN is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by sanofi-aventis U.S. LLC. The primary component is LIXISENATIDE.

    Product Information

    NDC 00024-5747
    Product ID 0024-5747_082cf774-e9b2-fdbd-e063-6294a90a6d61
    Associated GPIs 2717005600D230
    GCN Sequence Number 071734
    GCN Sequence Number Description lixisenatide PEN INJCTR 20 MCG/0.2 SUBCUT
    HIC3 C4I
    HIC3 Description ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST)
    GCN 35687
    HICL Sequence Number 040782
    HICL Sequence Number Description LIXISENATIDE
    Brand/Generic Brand
    Proprietary Name ADLYXIN
    Proprietary Name Suffix n/a
    Non-Proprietary Name Lixisenatide
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route SUBCUTANEOUS
    Active Ingredient Strength 100
    Active Ingredient Units ug/mL
    Substance Name LIXISENATIDE
    Labeler Name sanofi-aventis U.S. LLC
    Pharmaceutical Class GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA208471
    Listing Certified Through 2024-12-31

    Package

    NDC 00024-5747-02 (00024574702)

    NDC Package Code 0024-5747-02
    Billing NDC 00024574702
    Package 2 SYRINGE in 1 CARTON (0024-5747-02) / 3 mL in 1 SYRINGE
    Marketing Start Date 2016-07-27
    NDC Exclude Flag N
    Pricing Information N/A